Cancer patients with biomarker-positive tumors have better outcomes on immune checkpoint inhibitor therapy, a meta-analysis suggests.
Your search for non small cell lung cancer returned 15 results
The designation is supported by data from the ongoing phase 2 KEYNOTE-942 study, which included 157 patients with stage III/IV melanoma following complete resection.
Gavreto is an oral tyrosine kinase inhibitor.
Pemrydi RTU is expected to be available in the first quarter of 2024.
A regulatory decision is expected on November 27, 2023.
Keytruda is a programmed death receptor-1 (PD-1)-blocking antibody.
The approval was based on data from the KEYNOTE-091 trial.
The ready-to-dilute formulation was developed to eliminate the reconstitution step with Alimta.
Krazati is a highly selective and potent oral small molecule inhibitor of KRASG12C.
According to the CRL, the application could not be approved in its present form as additional data, including a randomized controlled trial, would be required.